A novel probiotic therapeutic in a murine model of *Clostridioides difficile* colitis

Rita D. Shelby*, Grace E. Janzow*, Lauren Mashburn-Warren*, Jeffrey Galley*, Natalie Tengberg*, Jason Navarro*, Miriam Conces*, Michael T. Bailey*, Steven D. Goodman*, and Gail E. Besner*

*Center for Perinatal Research, The Research Institute at Nationwide Children’s Hospital, Department of Pediatric Surgery, Nationwide Children’s Hospital, Columbus, OH, USA; †Center for Microbial Pathogenesis, The Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA; Department of Pathology, Nationwide Children’s Hospital, Columbus, OH, USA

**ABSTRACT**

*Clostridioides difficile* infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of *Lactobacillus reuteri* administered using a novel probiotic biofilm delivery system in the treatment and prevention of CDI in a murine model. For prophylactic therapy, mice received an oral antibiotic cocktail followed by clindamycin injection, followed by probiotic administration (planktonic vs. biofilm state), followed by *C. difficile* oral gavage. For treatment therapy, mice received antibiotics and *C. difficile* first, followed by probiotic administration. Clinical sickness scores (CSS) and intestinal histologic injury scores (HIS) were assigned. In the Prophylactic Therapy model, CSS: 67% of untreated mice exposed to *C. difficile* demonstrated CSS ≥ 6, which is consistent with *C. difficile* infection (p < 0.001 compared to unexposed mice). In mice treated with planktonic *Lr*, 55% had a CSS ≥ 6, but only 19% of mice treated with *Lr* in its biofilm state had CSS ≥ 6 (p < .001). Mice receiving *Lr* + DM-Maltose lost the least amount of weight compared to mice receiving saline (p = .004676) or to mice receiving *Lr* (p = .003185). HIS: 77% of untreated mice exposed to *C. difficile* had HIS scores ≥ 4, which is consistent with *C. difficile* infection. In mice treated with planktonic *Lr*, 62% had HIS ≥ 4, but only 19% of mice treated with *Lr* in its biofilm state had HIS ≥ 4 (p < .001). Additionally, mice treated with *Lr* in its biofilm state had better survival compared to untreated mice and to mice treated with planktonic *Lr* (p ≥ 0.05). Similar findings for weight loss, CSS, HIS, and survival were obtained for Treatment Therapy. A single dose of *Lactobacillus reuteri* in its biofilm state reduces the severity and incidence of experimental *C. difficile* infection when administered as both prophylactic and treatment therapy.

**Introduction**

*Clostridioides difficile* (*C. difficile*) colitis is an antibiotic-associated infection that has led to a significant healthcare crisis in developed countries, affecting over 500,000 individuals annually and causing ~30,000 deaths each year worldwide. In the United States alone, *C. difficile* results in an economic burden of 4.8 USD billion in associated health-care costs annually. The typical pathogenesis of the disease is commonly understood to start when the host is first predisposed by gut microbiome dysbiosis. This is often a result of receiving single- or multiple-dose antibiotic treatment, but it can result from other causes. Antibiotics lead to reduced microbial-produced secondary bile acids, and a resultant increase in primary bile acids. Some primary bile acids, such as taurocholate, increase germination of *C. difficile* spores, whereas secondary bile acids, such as ursodeoxycholic acid, inhibit germination and vegetative *C. difficile* growth. Disease induction occurs via release of toxins A and B, and intestinal epithelial cell internalization of these toxins. The toxins cause inflammation and tissue infiltration necrosis in the mucous layer and colonic epithelial cells of the host. This damage manifests in the host as severe diarrhea. The most common treatments available to patients afflicted with *C. difficile* colitis involve antibiotic administration. However, despite antibiotic treatment, *C. difficile* colitis often recurs. An estimated 20–30% of adult patients experience recurrent *C. difficile* infection. This recurrence can be associated with increased morbidity, require additional medication or longer courses of therapy, and can result in increased patient mortality. In
the most severe cases, care may also require fecal transplantation or colonic resection, but these procedures are not completely effective and are invasive.\textsuperscript{8,10}

Given the potential for antibiotic treatment inefficacy,\textsuperscript{4,10} as well as the need for effective treatment options for recurrent \textit{C. difficile} infection,\textsuperscript{4,8,10} further research is required. Probiotics have been previously shown to moderately restore eubiosis and reduce \textit{C. difficile} infection in high-risk patients receiving antibiotics.\textsuperscript{11} However, clinicians have been hesitant to adopt probiotic therapies due to the lack of ease of administration and inconsistent study results regarding long-lasting protection against \textit{C. difficile} colitis.\textsuperscript{3} Due to the increasing risk of \textit{C. difficile} colitis disease and recurrence in recent years, a defined methodology to track the progression, diagnosis and treatment options for this disease is not only beneficial but imperative. Our previous work supported this notion by establishing novel clinical and histological scoring systems that allow for efficient and accurate identification of diseased animals in an experimental murine model of \textit{C. difficile} colitis.\textsuperscript{12} We now incorporate these scoring systems to validate disease inoculation and to analyze the use of probiotics to prevent and treat \textit{C. difficile} infection.

Previous studies from our laboratory have demonstrated that \textit{Lactobacillus reuteri} (\textit{Lr}) can be induced to form a biofilm by incubation with biocompatible dextranomer microspheres (DM).\textsuperscript{13} Furthermore, these microspheres can be loaded with beneficial cargo such as sucrose or maltose in order to increase biofilm production. Compared to \textit{Lr} in its planktonic, free-living state, \textit{Lr} in its biofilm state has significantly increased efficacy in protecting the intestines from neonatal necrotizing enterocolitis,\textsuperscript{14,15} another disease associated with intestinal dysbiosis. Based on these findings, we now examine the ability of \textit{Lr} in its planktonic and biofilm state to protect the intestines from \textit{C. difficile} colitis.

**Materials and methods**

All experiments and procedures were reviewed and approved by the Nationwide Children’s Hospital Institutional Animal Care and Use Committee (IACUC Protocol # AR16-00095).

**Animals**

A combination of mice (conventional C57BL/6 mice) bred in house and commercially obtained (Jackson Laboratories, Bar Harbor, ME) was utilized. Only fully weaned 8- to 10-week old mice were utilized. All mice were housed under identical conditions in groups of no less than 3 and no greater than 5 mice per cage. They were fed an irradiated, soy-free, low-fat rodent diet product # 2920x.10 (Harlan, Indianapolis, IN). UV-sterilized drinking water was provided \textit{ad lib}. Animals were housed in a room designated only for \textit{C. difficile} experimentation. All bedding and enrichment toys were autoclaved to avoid the introduction of outside microbes.

**Antibiotic administration**

Antibiotics were administered over the course of 4 d in the form of a water cocktail as we have previously described.\textsuperscript{12} The water cocktail contained kanamycin (0.4 mg/mL), gentamicin (0.035 mg/mL), colistin (850 U/mL), metronidazole (0.215 mg/mL), and vancomycin (0.045 mg/mL), in the manner described by Julia et al.\textsuperscript{16} and by Chen et al.\textsuperscript{17} Antibiotics were purchased from Sigma-Aldrich (St. Louis, MO), reconstituted in sterile water, and provided to the mice \textit{ad libitum} in their drinking water. The antibiotic concentrations were calculated based on an average weight of the mice used (20–25 gm), and expected water consumption over 4 d (4–6 mL/mouse/day). Twenty-four hours after antibiotic cocktail completion, an intraperitoneal (IP) injection of clindamycin (10 mg/kg) prepared in sterile water was administered.

**Clostridioides difficile**

\textit{Clostridioides difficile} was prepared as we have described previously.\textsuperscript{12} Vegetative (non-sporulated) \textit{C. difficile} was prepared from a stock strain of VPI 10463 (ATCC 43255), which was purchased from the American Type Culture Collection (Manassas, VA). \textit{C. difficile} was grown anaerobically in Modified Reinforced Clostridial Medium (ATCC medium 2107). To remove dissolved oxygen to facilitate \textit{C. difficile} growth, the
medium was degassed by briefly boiling while bubbling with N₂ gas and reduced with 4 mM L-Cysteine, followed by pH adjustment to 6.8. *C. difficile* was grown in an anaerobic chamber in an atmosphere of 5% H₂/10% CO₂/85% N₂ at 37°C for 48 hours. Bacteria were centrifuged for 5 minutes at 8000 x g, the media removed, and the pellet washed twice and resuspended with sterile degassed PBS in an anaerobic atmosphere. The final dosage per animal achieved was 1.5 × 10⁷ CFU of vegetative *C. difficile* in 150 μl. Individual aliquots were made under anaerobic conditions to minimize oxygen exposure during mouse treatment.

The optimum dosage of vegetative *C. difficile* needed to establish colitis was determined in preliminary experiments. This was accomplished by gastric gavage of varying colony forming units (CFUs) (10⁶, 10⁷, 10⁸ and 10⁹) of vegetative *C. difficile* after receipt of the oral antibiotic cocktail and IP clindamycin. In addition to varying CFUs, different incubation time periods were also tested, obtaining vegetative cultures at 24 hours, 36 hours, and 48 hours of growth. The dosage of 1.5 × 10⁷ CFU grown in culture medium for 48 hours prior to administration was chosen based on the findings that this dose led to *C. difficile* colitis in a substantial number of mice but was not uniformly lethal. Each mouse received 150 μL of *C. difficile* solution by gastric gavage.

**Lr biofilm preparation**

Human-feces derived *L. reuteri* 23272 (American Type Culture Collection; ATCC, Manassas, VA) was grown overnight in Man, Rogosa, and Sharpe (MRS) broth (Fisher Scientific, Pittsburgh, PA) at 37°C in 5% CO₂. For planktonic *L. reuteri*, 1 × 10⁹ CFU/mL was pelleted and resuspended in sterile 0.9% saline prior to gastric gavage. For *L. reuteri* administered with unloaded microspheres, sterile dry dextranomer microspheres (Sephadex G-25 Superfine, GE Healthcare Bio-Sciences, Pittsburgh, PA) were hydrated in a sterile saline solution overnight. For *L. reuteri* administered with maltose-loaded microspheres, the microspheres were hydrated in a 1 M maltose solution in normal saline overnight. All microspheres were removed from the overnight solution via vacuum filter and aseptically transferred into a tube containing the resuspended bacteria. The bacteria were allowed to incubate with the microspheres for 1 hour at room temperature to facilitate binding. Each mouse received 200 μL of the bacterial solution by gastric gavage, for a final dose of 1 × 10⁸ CFU of *Lr*.

**Experimental model**

The experimental scheme of the *C. difficile* colitis models for prophylactic and therapeutic treatments are illustrated in Figures 1 and 2 respectively. The experimental models span a 15-day time period. In the prophylaxis experiments, following randomization into control or treatment groups, mice to be subjected to the *C. difficile* protocol were provided an antibiotic cocktail in sterilized drinking water over 4 d (days −8 to −4). Two days after oral antibiotic administration, mice received a single IP injection of clindamycin (day −2). Twenty-four hours after IP clindamycin, mice randomized to treatment groups received one dose of (1) saline (2) planktonic (*Lr*), or (3) *Lr*+ DM-maltose. A single gastric gavage dose of *C. difficile* was administered 24 hours after prophylactic treatment. Control mice received no antibiotics in their drinking water, saline gavage instead of probiotics gavage, and saline injection instead of *C. difficile* injection. Mice were observed for 6 d post treatment.

In the therapeutic experiments, following randomization into vehicle control and treatment groups, mice to be subjected to the *C. difficile* protocol again received an antibiotic cocktail over 4 d (days −8 to −4) followed 2 d later by a single IP injection of clindamycin (day −2). Twenty-four hours after the IP clindamycin, mice received a single dose of *C. difficile*. 24 h later, mice blindly randomized to treatment groups received one dose of (1) saline (2) planktonic *Lr*, (3) *Lr* + DM-water, or (4) *Lr*+ DM-maltose. Control mice received no antibiotics in their drinking water, saline injection instead of *C. difficile* injection, and saline gavage instead of probiotics gavage. Mice were observed for 6 d post *C. difficile* inoculation. Mice were weighed every other day. Symptoms of disease (stool characteristics, weight loss, and decreased response to stimuli) were recorded and mortality was tracked. Animals judged to be in a moribund state were euthanized. Tissue samples from the cecum and colon were taken for histopathologic analysis.
Changes in weight, clinical sickness scoring and histopathologic analysis

Mice were weighed and assigned clinical sickness scores (CSS) and histologic injury scores (HIS) in a blinded fashion, as we previously described. CSS is based on clinical symptoms of stool characteristics, behavioral change, and percent weight loss (Figure 3). Each category is scored from 0 to 4, and the individual values are added to provide an overall score (Figure...
A CSS of 6 or greater is considered consistent with *C. difficile* colitis, as we have previously reported. Animals achieving a CSS of ≥6 were euthanized. Upon sacrifice, the entire colon and cecum were collected for analysis. Histologic injury was graded based on epithelial tissue damage, amount of edema, and neutrophil infiltration (Figure 4). Each category was scored from 0 to 3 with the individual values added for an overall score. An HIS of ≥4 is indicative of *C. difficile* colitis, as we have previously reported.

### Statistical methods

Differences in CSS and HIS were assessed using analysis of variance (ANOVA) with protected t-tests used as post hoc tests, using each individual score assigned to each individual animal. Survival was assessed by Kaplan–Meier survival analysis and tested using the log-rank test. All analyses were conducted using the SAS 9.4 statistical software program (SAS Institute, Cary, NC) with two-sided p-values <0.05 considered statistically significant.

![Figure 4](image-url)  
**Figure 4.** Histologic injury scoring (HIS). Mouse colon histology illustrating tissue damage in mice afflicted with *C. difficile* colitis. Scores in these categories range from no injury (0) to severe injury (3), and are combined into a cumulative HIS score ranging from 0 to 9. A HIS of ≥4 is indicative of *C. difficile* colitis. LU, lumen; LP, lamina propria, S, submucosa, thick arrow, level of mucosal injury; thin arrow, superficial epithelium injury.
Results

*Lactobacillus reuteri* administered prophylactically in its biofilm state decreases the incidence and severity of *C. difficile* colitis and improves survival

For these experiments, probiotics were administered as prophylaxis prior to *C. difficile* administration.

**Weight loss**

Control mice maintained their original body weight (Figure 5). Animals receiving *Lr* + DM-Maltose lost the least amount of weight compared to animals receiving saline (*p* = .005) and compared to animals receiving *Lr* (*p* = .003). There was no difference in the percent of weight loss between animals receiving saline vs. *Lr* (*p* = .889).

*CSS*

Control mice that were not subjected to the *C. difficile* protocol did not develop signs of sickness. Compared to control mice, 67% of mice subjected to the *C. difficile* protocol that received saline only had CSS scores >6, consistent with *C. difficile* infection (*p* < .001) (Figure 6). Fifty-one percent of those animals had severe clinical signs of sickness with CSS ≥9. There was no significant difference in the incidence of clinical sickness in mice subjected to the *C. difficile* protocol that had prophylaxis with planktonic *Lr* compared to mice that received saline only (*p* = .553). However, compared to mice that received saline only, mice that received prophylaxis with a single dose of *Lr* + DM-maltose (*Lr* in its biofilm state) had a significantly lower incidence of CSS score ≥6 (*p* < .001).

![Figure 5](image-url) - Percent of original body weight in CDI prophylaxis. Control mice received no antibiotics, no probiotics, and no *C. difficile*. Mice subjected to the *C. difficile* protocol were randomized to receive one dose of: (1) saline (2) planktonic *Lr*, or (3) *Lr* + DM-maltose. Weight was measured every other day. All 5 Control mice maintained their original body weights, indicated by the mean and bar range at 100%. Animals receiving *Lr* + DM-Maltose lost the least amount of weight compared to animals receiving saline (*p* = .004676) or compared to animals receiving *Lr* (*p* = .003185). There was no difference in percent of weight loss between animals receiving saline vs. *Lr* (*p* = .888959).
Control mice that were not subjected to the *C. difficile* protocol did not develop histologic injury. Compared to control mice, 77% of mice subjected to the experimental *C. difficile* protocol that received saline only had HIS scores ≥4, which is consistent with *C. difficile* infection ($p < .001$) (Figure 7). Forty-seven percent of those animals had a severe histological injury with HIS ≥7.

There was no significant difference in the incidence of histologic injury in mice subjected to the *C. difficile* protocol that had prophylaxis with planktonic *Lr* compared to mice that received saline only ($p = .379$). However, compared to mice that received saline only, mice that received prophylaxis with a single dose of *Lr* + DM-maltose (*Lr* in its biofilm state) had a significantly lower incidence of HIS ≥4 ($p < .001$).
Survival
Kaplan–Meier survival analysis revealed a significant difference in animal survival in mice exposed to the prophylactic C. difficile protocol treated with saline only compared to mice that were treated with a single dose of Lr + DM-Maltose at the end of the experiment on Day 6 (48% vs. 78%; p < .05) (Figure 8). There was no significant difference in the survival of mice treated with saline only compared to planktonic Lr treated mice within this experimental timeframe (48% vs. 59%, p > .05) (Figure 8).

Lactobacillus reuteri administered therapeutically in its biofilm state decreases the incidence and severity of C. difficile colitis and improves survival
For these experiments, probiotics were administered as a treatment after C. difficile infection was already established.

Weight loss
Control mice maintained their original body weight. Animals receiving Lr + DM-Maltose and Lr + DM-Water lost the least amount of weight compared to animals receiving saline (p = .0043 and 0.0067, respectively), whereas there was no difference in percent weight loss between animals receiving Lr vs. saline (p = .0628) (Figure 9). There was no difference in the percent of weight loss between animals receiving Lr + DM-Maltose or Lr + DM-Water vs. Lr (p = .4591 and p = .6790, respectively).

CSS
Control mice that were not subjected to the C. difficile protocol did not develop signs of sickness. Compared to control mice, 67% of mice subjected to the experimental C. difficile protocol that received saline only had CSS scores ≥6, consistent with C. difficile infection (p < .001) (Figure 10). All of these animals had CSS scores consistent with severe signs of sickness (CSS ≥9). There was no significant difference in the incidence of clinical sickness scores in mice subjected to the C. difficile protocol that were treated with planktonic Lr compared to mice that received saline only (p = .056). However, compared to mice that received saline only, mice that received a single dose of Lr + DM-water had a decreased incidence of CSS ≥6 (p = .008), and mice treated with Lr + DM-maltose had a further decrease in the incidence of CSS ≥6 (p = .014).

HIS
Control mice that were not subjected to the C. difficile protocol did not develop histologic injury. Compared to control mice, 66% of mice subjected to the C. difficile protocol that received saline only had HIS scores ≥4, consistent with C. difficile infection (p = .002) (Figure 11). Fifty-three percent of those animals had HIS scores consistent with severe histological injury with HIS ≥7. There was no significant difference in the incidence of histologic injury in mice subjected to the C. difficile protocol that were not subjected to histologic injury.

Figure 8. Survival in CDI prophylaxis. Control mice received no antibiotics, no C. difficile and no probiotics. Mice subjected to the C. difficile protocol were randomized to receive one dose of: (1) Saline (2) Planktonic Lr, (3) Lr + DM-Water or (4) Lr + DM-Maltose. Kaplan–Meier survival curve demonstrating percent death and survival of animals in each treatment group over the time course of the experiment.
treated with planktonic Lr compared to mice that received saline only (p = 0.263). However, compared to mice that received a single dose of Lr + DM-Maltose, mice that received Lr + DM-Water lost the least amount of weight (p = 0.0043 and 0.0067, respectively). There was no difference in percent of weight loss between animals receiving saline vs. Lr (p = 0.0628). There was no difference in percent of weight loss between animals receiving Lr + DM-Maltose or Lr + DM-Water vs. Lr (p = 0.4591 and p = 0.6790, respectively).

**Figure 9.** Percent of original body weight in CDI therapy. Control mice received no antibiotics, no probiotics, and no C. difficile. Mice subjected to the C. difficile protocol were randomized to receive one dose of: (1) saline (2) planktonic Lr, (3) Lr + DM-maltose, or (4) Lr + DM-maltose. Weight loss was measured every other day. All 5 Control mice maintained their original body weights, indicated by the mean and bar range at 100%. Animals receiving Lr + DM-Maltose and Lr + DM-Water lost the least amount of weight compared to animals receiving saline (p = 0.0043 and 0.0067, respectively). There was no difference in percent of weight loss between animals receiving saline vs. Lr (p = 0.0628). There was no difference in percent of weight loss between animals receiving Lr + DM-Maltose or Lr + DM-Water vs. Lr (p = 0.4591 and p = 0.6790, respectively).

**Figure 10.** Clinical sickness score (CSS) grading with CDI therapy. Control mice received no antibiotics, no C. difficile and no probiotics. Mice subjected to the C. difficile protocol were randomized to receive one dose of: (1) saline (2) planktonic Lr, (3) Lr + DM-water or (4) Lr + DM-maltose. Clinical sickness scores were assigned with daily observation. Total CCS for each animal ranges from 0 to 12 as illustrated in Figure 3. Each colored symbol represents one animal. Animals with scores ≥ 6 have CSS consistent with clinical C. difficile infection. The percentages at the top of each treatment group reflect the percent of animals with CSS ≥ 6 for each group. All p values are calculated based on individual animal scores.
Water had a decreased incidence of histologic injury ≥4 consistent with *C. difficile* infection (*p* = .022), and mice treated with *Lr* + DM-Maltose had a further and significant decrease in histologic injury ≥4 (*p* = .004).

**Survival**

Kaplan–Meier survival analysis revealed a significant difference in animal survival between saline-treated mice and mice that received a single dose of *Lr* + DM-Maltose therapeutically by the end of the experiment on Day 6 (42% vs. 78%; *p* < .05) (Figure 12). There was also a significant difference in survival between animals that received *Lr* + DM-Maltose and those that received planktonic *Lr* at Day 6 (78% vs. 50%; *p* < .05). There was no significant difference in survival of mice that received a single dose of *Lr* + DM-Maltose compared to those that received *Lr* + DM-Water by Day 6 (78% vs. 66%, *p* > .05).

**Discussion**

The incidence of *C. difficile* colitis is rising in both pediatric and adult populations.\(^1,\!^{18}\) Despite this, the management of *C. difficile* colitis still requires optimization. At present, the most common instigator that leads to the development of *C. difficile*, antibiotics, is also the first-line treatment option for both initial and recurrent *C. difficile* colitis.\(^8,\!^{11,\!^{18}}\)
However, in spite of these established therapies, many patients often have a number of recurrent infections that are resistant to antibiotic therapy. Additionally, disease in some patients can rapidly escalate in severity, leaving no other treatment option but surgical intervention.\textsuperscript{11,19,20}

With the continued rise in the incidence of initial and recurrent disease, as well as associated complications, there has been an increased interest in the development of alternative therapies. In particular, probiotics have been of significant interest in the treatment and prevention of \textit{C. difficile} colitis.\textsuperscript{3,11,21} Probiotics are theoretically efficacious because of their potential to restore eubiosis to the gastrointestinal microbiota after disruption by antimicrobials.\textsuperscript{22} There have been several studies recently published supporting the use of probiotics for their protective effect against \textit{C. difficile} infection.\textsuperscript{3,23} However, to date, only moderate efficacy of the several probiotics used has been obtained.\textsuperscript{24–27} It is important to note that in all of these studies and analyses, probiotics were evaluated in the \textit{prevention} of \textit{C. difficile} colitis and not in the treatment of the disease. Furthermore, in all of these studies, probiotics were administered in their planktonic state and required repeated doses to demonstrate efficacy.\textsuperscript{28,29} In the current study, we have demonstrated that the administration of one single dose of \textit{Lr} in its biofilm state can significantly reduce the incidence and severity of \textit{C. difficile} colitis when administered either prophylactically or therapeutically.

\textit{Lr} is present in the healthy human intestinal tract and was originally isolated from human breast milk.\textsuperscript{30,31} The current studies utilized clade II \textit{Lr} (ATCC 23272) originally isolated from human stool. This strain of \textit{Lr}, among others, has antimicrobial activity conferred by its ability to convert glycerol into the antimicrobial compound reuterin, and it has anti-inflammatory properties due to its ability to produce histamine and to modulate cytokine production.\textsuperscript{32,33} \textit{Lr} also readily forms a biofilm and has a significant affinity for the cross-linked dextran in DM. Because of these properties, as well as our own experience with this probiotic formulation in the prevention of necrotizing enterocolitis (NEC),\textsuperscript{14,15} we chose to use \textit{Lr} for our experimental model.

In the current study, we found no efficacy of a single dose of \textit{Lr} administered in its planktonic state either prophylactically or therapeutically. On the other hand, we were able to demonstrate efficacy with the administration of just one single dose of \textit{Lr} administered in its biofilm state. Other strains of planktonic \textit{Lr} have demonstrated various levels of efficacy with repeated multi-dose delivery in other studies.\textsuperscript{3,24,34} Britton et al. demonstrated that \textit{Lr} as ‘precursor-directed antimicrobial therapy’ is effective in targeting CDI. In addition, they argue that antimicrobial resistance can be leveraged in the natural human microbiome response to evade \textit{C. dif} – demonstrating the efficacy of administering \textit{Lr} as a prophylactic probiotics.\textsuperscript{23} This is similar to our prophylactic results; however, in our studies, the best efficacy was noted in our novel formulation of \textit{Lr} adhered to maltose-loaded DM, where there is the greatest biofilm formation. We have previously shown that \textit{Lr} in its biofilm state demonstrates prolonged survival in acidic environments and improved adherence to intestinal epithelial cells \textit{in vitro}\textsuperscript{13,15} and protects the intestines from NEC \textit{in vivo}.\textsuperscript{14,15} In our NEC studies, augmentation of biofilm formation by adherence of \textit{Lr} to DM loaded with sucrose or maltose leads to increased intestinal protection,\textsuperscript{14} and conversely, decreasing the ability of \textit{Lr} to produce a biofilm by using a genetically altered strain of \textit{Lr} (\textit{ΔgtfW}) decreases intestinal protection.\textsuperscript{14}

The adherence of \textit{Lr} to DM to promote biofilm formation is a central component of its improved protective effect seen in this study. \textit{Lr} relies on a novel extracellular glucosyltransferase (GtfW), rare among bacteria, that does not rely on sugar nucleotide intermediates but uses the energy of existing glycosidic linkages to generate chains of polysaccharides. Indeed, \textit{Lr} adheres to DM via the glucan-binding domain of the GtfW enzyme\textsuperscript{14} as well as the ability to directly use maltose to make glucan homopolymers that facilitate binding to DM. Importantly, we have previously shown that \textit{Escherichia coli}, \textit{Salmonella typhimurium}, and \textit{Clostridiodes difficile} do not detectably bind to DM,\textsuperscript{13} allaying any concerns that the administration of DM might provide a platform for increased biofilm formation in pathogenic bacteria.

A limitation of the current work is that an analysis of the gut microbiome after antibiotic
administration *C. difficile* inoculation or probiotic therapy was not performed. However, we have investigated the effect of *L. reuteri* in its biofilm state on the incidence and severity of necrotizing enterocolitis (NEC), and in those studies we were able to demonstrate a change in the microbiome when *L. reuteri* was administered in its biofilm compared to its planktonic state. Based on this, a change in microbiome may also play a role in our *C. difficile* studies, and will be addressed in future studies.

The novel formulation presented here represents a potential exciting development toward improving probiotic therapy for a devastating public health problem. Our results showing that *Lr* in its biofilm state is superior to planktonic *Lr* provide great insight into future potential therapeutics.

Conclusion

*Lr* administered in its biofilm state exhibits a protective effect against *C. difficile* colitis when administered both prophylactically and as a treatment, with just one single dose. These results support the future translation of this treatment to the bedside given the dual efficacy of this probiotic.

Acknowledgments

We thank Yijie Wang (Nationwide Children’s Hospital, Laboratory of Dr. Gail Besner) who played an integral role in experiment concept and design, obtaining all necessary supplies, animals, and overall function of the experiments.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

References

1. Lessa FC, Winston LG, McDonald LC, Team ELPCdS. Burden of clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369–2370. doi:10.1056/NEJMoa1408913.
2. Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerdin DN, Saeed MJ, Mahé C, Dubberke ER. The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. administrative databases. BMC Infect Dis. 2016;16(1):177. doi:10.1186/s12879-016-1501-7.
3. Mills JP, Rao K, Young VB. Probiotics for prevention of clostridium difficile infection. Curr Opin Gastroenterol. 2018;34(1):3–10. doi:10.1097/MOG.0000000000000410.
4. Dieterle MG, Young VB. Reducing recurrence of *C. difficile* infection. Cell. 2017;169(3):375. doi:10.1016/j.cell.2017.03.039.
5. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190(7):2505–2512. doi:10.1128/JB.01765-07.
6. Weingarden AR, Chen C, Zhang N, Graziiger CT, Dosa PI, Steer CJ, Shaughnessy MK, Johnson JR, Sadowsky MJ, Khoruts A, et al. Ursodeoxycholic acid inhibits clostridium difficile spor germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol. 2015;50(8):624–630. doi:10.1097/MCG.0000000000000427.
7. Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol. 2016;14(10):609–620. doi:10.1038/nrmicro.2016.108.
8. Evans CT, Safdar N. Current trends in the epidemiology and outcomes of clostridium difficile infection. Clin Infect Dis. 2015;60(suppl 2):S66–S71. doi:10.1093/cid/civ140.
9. Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 2016;29(2):147–154. doi:10.20524/aog.2016.0006.
10. Nicholson MR, Thomsen IP, Slaughter JC, Creech CB, Edwards KM. Novel risk factors for recurrent clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2015;60(1):18–22. doi:10.1097/MPG.0000000000000553.
11. Maziade PJ, Pereira P, Goldstein EJ. A decade of experience in primary prevention of clostridium difficile infection at a community hospital using the probiotic combination lactobacillus acidophilus CL1285, lactobacillus casei LBC80R, and lactobacillus rhamnosus CLSR2 (Bio-K+). Clin Infect Dis. 2015;60(Suppl 2):S144–147. doi:10.1093/cid/civ178.
12. Shelby RD, Tengberg N, Conces M, Olson JK, Navarro JB, Bailey MT, Goodman SD, Besner GE. Development of a standardized scoring system to assess a murine model of clostridium difficile colitis. J Invest Surg. 2019;1:9. doi:10.1080/08941939.2019.1571129.
13. Navarro JB, Mashburn-Warren L, Bakaletz LO, Bailey MT, Goodman SD. Enhanced probiotic potential of *Front Microbiol*. 2017;8:489.
14. Olson JK, Navarro JB, Allen JM, McCulloh CJ, Mashburn-Warren L, Wang Y, Varaljay VA, Bailey MT, Goodman SD, Besner GE, et al. An enhanced lactobacillus reuteri biofilm formulation that increases protection against experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2018;315(3):G408–G419. doi:10.1152/ajpgi.00078.2018.
15. Olson JK, Rager TM, Navarro JB, Mashburn-Warren L, Goodman SD, Besner GE. Harvesting the benefits of
biofilms: A novel probiotic delivery system for the prevention of necrotizing enterocolitis. J Pediatr Surg. 2016;51(6):936–941. doi:10.1016/j.jpedsurg.2016.02.062.

16. Julia V, McSorley SS, Malherbe L, Breitmayer J-P, Girard-Pipau F, Beck A, Glaienhauss N. Priming by microbial antigens from the intestinal flora determines the ability of CD4+ T cells to rapidly secrete IL-4 in BALB/c mice infected with leishmania major. J Immunol. 2000;165(10):5637–5645. doi:10.4049/jimmunol.165.10.5637.

17. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. A mouse model of clostridium difficile-associated disease. Gastroenterology. 2008;135(6):1984–1992. doi:10.1053/j.gastro.2008.09.002.

18. D’Ostroph AR, So TY. Treatment of pediatric. Infect Drug Resist. 2017;10:365–375. doi:10.2147/IDR.S119571.

19. Hall BR, Armijo PR, Leinicke JA, Langenfeld SJ, Oleynikov D. Prolonged non-operative management of clostridium difficile colitis is associated with increased mortality, complications, and cost. Am J Surg. 2019;217(6):1042–1046. doi:10.1016/j.amjsurg.2019.01.017.

20. Hall JF, Berger D. Outcome of colectomy for clostridium difficile colitis: a plea for early surgical management. Am J Surg. 2008;196(3):384–388. doi:10.1016/j.amjsurg.2007.11.017.

21. Valdés-Varela L, Gueimonde M, Ruas-Madiedo P. Probiotics for prevention and treatment of clostridium difficile infection. Adv Exp Med Biol. 2018;1050:161–176.

22. Dinleyici M, Vandenplas Y. Clostridium difficile Colitis Prevention and Treatment. Adv Exp Med Biol. 2019;1125:139–146.

23. Spínler JK, Auchtung J, Brown A, Boonma P, Oezguen N, Ross CL, Luna RA, Runge J, Versalovic J, Peniche A, et al. Next-generation probiotics targeting clostridium difficile through precursor-directed antimicrobial biosynthesis. Infect Immun. 2017;85(10):10. doi:10.1128/IAI.00303-17.

24. Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827.

25. Goldenberg JZ, Mertz D, Johnston BC. Probiotics to prevent clostridium difficile infection in patients receiving antibiotics. JAMA. 2018;320(5):499–500. doi:10.1001/jama.2018.9064.

26. Johnson S, Maziade PJ, McFarland LV, Trick W, Donskey C, Currie B, Low DE, Goldstein EJC. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis. 2012;16(11):e786–792. doi:10.1016/j.ijid.2012.06.005.

27. Goldstein EJC, Johnston SJ, Maziade PJ, Evans CT, Sniffen JC, Millette M, McFarland LV. Probiotics and prevention of clostridium difficile infection. Anaerobe. 2017;45:114–119. doi:10.1016/j.anaerobe.2016.12.007.

28. Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsey J, Mertz D, Johnston BC. Probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095.

29. Johnston BC, Lytvyn L, Lo CK, Allen SJ, Wang D, Szajewska H, Miller M, Ehrhardt S, Sampalis J, Duman DG, et al. Microbial preparations (Probiotics) for the prevention of clostridium difficile infection in adults and children: an individual patient data meta-analysis of 6,851 participants. Infect Control Hosp Epidemiol. 2018;39(7):771–781. doi:10.1017/ice.2018.84.

30. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microb. 2001;2:43–53.

31. Urbaniksa M, Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. Eur J Pediatr. 2014;173(10):1327–1337. doi:10.1007/s00431-014-2328-0.

32. Spinler JK, Sontakke A, Hollister EB, Venable SF, Oh PL, Balderas MA, Saulnier DMA, Mistretta T-A, Devaraj S, Walter J, et al. From prediction to function using evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse probiotic functions. Genome Biol Evol. 2014;6(7):1772–1789. doi:10.1093/gbe/evu137.

33. Spinler JK, Taweechotipat M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe. 2008;14(3):166–171. doi:10.1016/j.anaerobe.2008.02.001.

34. Rao K, Young VB. Probiotics for prevention of clostridium difficile infection in hospitalized patients: is the jury still out? Gastroenterology. 2017;152(8):1817–1819. doi:10.1053/j.gastro.2017.04.027.